Sonja Woods, MD
Family Medicine · Greeneville, TNNPI 1104853639
Payments from drug & device makers
Across 398 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$870
- Pfizer$815
- Novo Nordisk$718
- Lilly USA, LLC$512
- Boehringer Ingelheim$431
- AstraZeneca$276
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,129100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $870 |
| Pfizer | 59 | $815 |
| Novo Nordisk | 48 | $718 |
| Lilly USA, LLC | 33 | $512 |
| Boehringer Ingelheim | 14 | $431 |
| AstraZeneca | 18 | $276 |
| Amgen | 17 | $243 |
| Bayer | 13 | $240 |
| GSK | 14 | $235 |
| Merck | 20 | $215 |
| Novartis | 12 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $189 |
| Amarin Pharma, Inc. | 9 | $159 |
| Dexcom, Inc. | 5 | $107 |
| Welch Allyn | 2 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $96 |
| Sanofi-aventis U.S. LLC | 6 | $83 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Johnson & Johnson | 5 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Sumitomo Pharma America, Inc. | 4 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Corcept Therapeutics | 2 | $36 |
| Exact Sciences | 2 | $32 |
| Medtronic(2 entities) | 2 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 2 | $17 |
| Teleflex LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
| Mannkind Corporation | 1 | $11 |
How this compares
$6,130 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $119,627 |
| EliquisApixaban | 88 | $84,694 |
| MounjaroTirzepatide | 70 | $77,201 |
| TrulicityDulaglutide | 21 | $32,497 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 134 | $30,446 |
| FarxigaDapagliflozin Propanediol | 38 | $27,981 |
| JanuviaSitagliptin Phosphate | 25 | $27,534 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 76 | $24,761 |
| LinzessLinaclotide | 27 | $21,888 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,199 |
| JardianceEmpagliflozin | 12 | $14,740 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $14,627 |
| MyrbetriqMirabegron | 21 | $14,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $13,661 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $10,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $718 | $119,627111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $512 | $109,69891 claims |
| PfizerEliquis, Abrysvo | $815 | $109,455164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $276 | $52,90477 claims |
| GSKShingrix, Trelegy Ellipta, Arexvy | $235 | $51,880180 claims |
| MerckJanuvia | $215 | $27,53425 claims |
| AbbVieLinzess | $870 | $21,88827 claims |
| Boehringer IngelheimJardiance | $431 | $14,74012 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $14,07821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $96 | $5,12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Greeneville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.